The FFR-IQ software recently demonstrated a 92.2 percent sensitivity for non-invasive estimation of fractional flow reserve (FFRC) based on coronary CT angiography (CCTA) scans.
|Articles|November 27, 2009
Agfa to acquire European maker of contrast media
Agfa HealthCare has signed an agreement with Curagita Holding AG to acquire all the shares of its subsidiary Insight Agents GmbH, a German-based developer and producer of generic contrast media.
Advertisement
Agfa HealthCare has signed an agreement with Curagita Holding AG to acquire all the shares of its subsidiary Insight Agents GmbH, a German-based developer and producer of generic contrast media. Agfa expects to pay about 10 million Euros for the contrast media firm in a deal that the Belgian company is framing as an important strategic step towards future growth opportunities. Insight Agents makes generic contrast media, including the MR contrast agent Magnegita (gadopentetate dimeglumine), a generic form of Magnevist, and Iopamigita (Iopamidol), a generic form of Isovue. Insight’s contrast media are logical additions to Agfa’s portfolio of film, chemicals, and printers, according to Christian Reinaudo, president of Agfa HealthCare. They will be distributed through the company’s extensive logistics and distribution network, he said.
Advertisement
Related to this article
Catch up on the top radiology content of the past week.
While a new article raises provocative questions about the capability of photon-counting CT (PCCT) to perhaps replace diagnostic ICA, the real revolution with this modality is going beyond stenosis measurement to a renewed focus on the disease of atherosclerosis.
The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
Catch up on the top radiology content of the past week.
Catch up on the top radiology content of the past week.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Can MRI-Based AI Have an Impact in Reducing Unnecessary Prostate Biopsies?
2
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
3
FDA Clears AI-Enabled FFR-IQ Software for Estimating Fractional Flow Reserve from CCTA
4
The Reading Room Podcast: A Closer Look at New Research on 177Lu-Edotreotide for Treating GEP-NETs
5